Drugs / Synthetic Tumor-Specific Breakpoint Peptide Vaccine
Synthetic Tumor-Specific Breakpoint Peptide Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00267085 | Dec 2005 → Jul 2008 | chronic myeloid leukemia | M.D. Anderson Cancer Center | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Synthetic Tumor-Specific Breakpoint Peptide Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00267085 ↗ |
| Modality | Vaccine | “CML-VAX B2 and CML-VAX B3 are experimental vaccines made from the proteins that cause leukemia cells in CML to behave abnormally.” NCT00267085 ↗ |
| Route | Subcutaneous | “CML vaccine, Imatinib mesylate, subcutaneously every 2 weeks x 4 weeks, then every three weeks x 1 week, then monthly for 10 months” NCT00267085 ↗ |